STO · SOBI.ST
Swedish Orphan Biovitrum AB
SEK 488.00+SEK 9.80 (+2.05%)
Swedish Orphan Biovitrum AB’s quoted price sits in the upper half of its reported 52-week range, 0.81% below the high.
Loading market information…
STO · HNSA.ST · SEK
Stock price, earnings
Quote as of Oct 29, 2026, 04:29 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Hansa Biopharma AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 18.42% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Hansa Biopharma AB (publ)’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of SEK 3.17. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Hansa Biopharma AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Hansa Biopharma AB (publ) is a biopharmaceutical firm dedicated to developing immunomodulatory therapies. Leveraging its unique enzyme technology platform, the company targets treatments that facilitate organ transplants and address rare autoimmune conditions driven by immunoglobulin G (IgG), alongside applications in gene therapy and cancer. Its primary drug candidate, Imlifidase, an enzyme therapy designed to cleave antibodies, is currently undergoing Phase 3 clinical trials for use in patients awaiting sensitized kidney transplants and those with anti-GBM antibody disease. Imlifidase is also in Phase 2 trials for treating antibody-mediated kidney transplant rejection and Guillain Barré syndrome. Further pipeline developments include NiceR (Novel immunoglobulin cleaving enzymes for Repeat dosing) for autoimmune diseases, transplantation, and oncology, as well as EnzE (Enzyme based antibody Enhancement) for cancer immunotherapy. Hansa Biopharma also has a preclinical research partnership with argenx BV, exploring the synergistic potential of their respective IgG-modulating technologies. Established in 2007, the company's headquarters are located in Lund, Sweden.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:37 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | Apr 24, 2025 | -SEK 0.55+79.4% vs estimate | SEK 66.35M-5.82% vs estimate |
|---|
| Q4 2024 | Feb 6, 2025 | -SEK 4.08-121.74% vs estimate | SEK 32.34M-60.32% vs estimate |
|---|
| Q3 2024 | Oct 17, 2024 | -SEK 1.53+36.78% vs estimate | SEK 48.66M-10.23% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 488.00+SEK 9.80 (+2.05%)
Swedish Orphan Biovitrum AB’s quoted price sits in the upper half of its reported 52-week range, 0.81% below the high.
SEK 273.40+SEK 1.50 (+0.55%)
Getinge AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 0.18% below the high.
SEK 16.76-SEK 0.72 (-4.12%)
SynAct Pharma AB’s quoted price sits in the upper half of its reported 52-week range, 31.87% below the high.
SEK 1.67+SEK 0.20 (+13.2%)
Cantargia AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 74.63% below the high.
SEK 5.71-SEK 14.99 (-72.42%)
BioInvent International AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 83.62% below the high.
SEK 1.00+SEK 0.02 (+2.45%)
Diamyd Medical AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 94.38% below the high.
SEK 0.38+SEK 0.00 (+1.08%)
Alzinova AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 81.86% below the high.
SEK 3.83+SEK 0.03 (+0.66%)
Active Biotech AB’s quoted price sits in the lower half of its reported 52-week range, 59.44% below the high.
